UPDATE: RBC Capital Starts FibroGen (FGEN) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to UPDATE: RBC Capital Starts FibroGen (FGEN) at Outperform
December 9, 2014 7:39 AM EST
Stifel initiated coverage on FibroGen (NASDAQ: FGEN) with a Buy rating and a price target of $39.00.
For an analyst ratings summary and ratings history on FibroGen click here. For more ratings news on FibroGen click here.
Shares of FibroGen closed at $28.00 yesterday.
...
More
December 9, 2014 7:38 AM EST
Goldman Sachs initiates coverage on FibroGen (NASDAQ: FGEN) with a Buy rating and a price target of $32.00.
Analyst Terence Flynn said, "Based on the Roxa Phase 2 data we see three potential benefits over injectable ESAs potential to improve safety (focus will be on... More
December 8, 2014 7:42 AM EST
William Blair initiated coverage on FibroGen (NASDAQ: FGEN) with an Outperform rating.
Analyst John Sonnier estimated that the company would generate revenue of $136 million in 2014 and $191 million in 2015, and believes the company has sufficient capital to sustain itself for at least two years.
"Our bullish investment outlook on FibroGen is based on a variety of factors," Sonnier said. "These include the strength of lead product candidates roxadustat, which is... More
